MaxWell Biosystems

Executive Summary

MaxWell Biosystems is a Swiss biotechnology company pioneering high-density microelectrode array (HD-MEA) technology for advanced in vitro electrophysiology. Its platforms enable high-resolution recording and stimulation of neuronal activity, accelerating basic neuroscience research and preclinical drug discovery. Founded in 2017 and headquartered in Zurich, the company serves academic and pharmaceutical customers seeking to bridge the gap between cellular assays and clinical outcomes. By providing label-free, real-time functional measurements of neural networks, MaxWell addresses a critical need in CNS drug development, where current tools often fail to predict human responses. The company's technology is positioned to capitalize on growing demand for more predictive preclinical models, particularly in neuropsychiatric and neurodegenerative diseases. With a strong intellectual property portfolio and a commercially available product line, MaxWell has established collaborations with leading research institutions. As the field moves toward human-relevant in vitro models, MaxWell's HD-MEA platforms offer a scalable solution for functional phenotyping. The company is now seeking to expand its commercial footprint and secure funding for next-generation product development, targeting key milestones in the near term.

Upcoming Catalysts (preview)

• Q4 2026Series B Financing Round65% success
• Q2 2027Strategic Partnership with Top-20 Pharma for CNS Drug Screening40% success
• Q3 2026Launch of Next-Generation HD-MEA Chip with Enhanced Throughput60% success